Archives

  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-07

    • ATS-9R: Non-Viral Gene Delivery to White Adipose Tissue

    2026-02-04

    ATS-9R: Non-Viral Gene Delivery to White Adipose Tissue

    Introduction: Principle and Setup for Adipocyte-Targeted Delivery

    Advances in metabolic disease research demand delivery systems that can precisely modulate gene expression in adipose tissue—without the safety concerns of viral vectors. ATS-9R (Adipocyte-targeting sequence-9-arginine), supplied by APExBIO, is a non-viral gene delivery fusion oligopeptide that uniquely addresses this challenge. By exploiting prohibitin-mediated endocytosis, ATS-9R achieves highly specific delivery of nucleic acids to mature adipocytes and visceral adipose tissue macrophages (ATMs), bypassing the low transfection efficiencies that previously limited adipocyte gene therapy (Won et al., 2014).

    ATS-9R comprises a Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Cys peptide, where a nona-arginine (9R) motif enhances both nucleic acid condensation and cellular uptake. The peptide's affinity for prohibitin, a protein overexpressed on mature adipocytes, enables targeted white adipose tissue delivery, resulting in efficient intracellular gene silencing. This unique mechanism positions ATS-9R as a leading tool for obesity-associated inflammation research, insulin resistance amelioration, gestational diabetes mellitus (GDM) modeling, and studies in obesity-induced type 2 diabetes.

    Step-by-Step Experimental Workflow with ATS-9R

    Reagent Preparation and Storage

    • Peptide Solubilization: Dissolve ATS-9R in DMSO to prepare a stock solution. Store aliquots at -20°C, protected from light and repeated freeze-thaw cycles, to maintain targeting efficiency.
    • Nucleic Acid Complexing: Use high-purity shRNA, siRNA, or sgRNA/Cas9 complexes. For optimal nanoparticle formation, mix ATS-9R and nucleic acids at a 3:1 or 6:1 weight ratio.
    • Complex Validation: Confirm nanoparticle formation (150–354 nm, zeta potential 7–20 mV) via dynamic light scattering and verify condensation efficiency using an agarose gel retardation assay.

    In Vitro Transfection Protocol

    1. Cell Seeding: Plate preadipocytes or mature adipocytes (e.g., 3T3-L1 or primary cultures) in serum-free medium.
    2. Complex Addition: Add ATS-9R/nucleic acid complexes at a final concentration of 10–25 μg/ml peptide and 5 μM–2 μg nucleic acid.
    3. Incubation: Incubate for 4–6 hours at 37°C, then replace with complete medium.
    4. Gene Knockdown Assessment: Analyze mRNA/protein levels of the target (e.g., TACE, CCL2, FAM83A, Fabp4) after 24–72 hours using qPCR or Western blot.

    In Vivo Delivery in Animal Models

    • Complex Preparation: Prepare fresh ATS-9R/nucleic acid complexes before each injection.
    • Dosage: Administer 0.2–0.35 mg/kg ATS-9R (with 0.35–0.7 mg/kg nucleic acid) via intraperitoneal injection, twice weekly or as four consecutive doses.
    • Tissue Distribution: Expect preferential accumulation in visceral (epiWAT) and subcutaneous (subWAT) adipose tissue. Minimal liver uptake is observed, with hepatic clearance occurring within 12–24 hours (Won et al., 2014).
    • Efficacy Monitoring: Achieve 30%–70% knockdown of target gene mRNA, with no significant cytotoxicity (cell viability >80%) or adverse hepatic/renal effects.

    Advanced Applications and Comparative Advantages

    1. Precision Gene Silencing in Obesity Models: ATS-9R enables targeted knockdown of lipid metabolism and inflammatory genes (e.g., Fabp4, CCL2), resulting in significant metabolic recovery and body weight reduction (>20% in obese mice treated with ATS-9R/shFabp4, Won et al., 2014).

    2. Insulin Resistance and GDM Research: The ability to silence genes in visceral and subcutaneous adipose tissue allows for mechanistic studies on insulin signaling and gestational diabetes, a key advantage over systemic or liver-targeted approaches.

    3. Safety Profile: As a non-viral vehicle, ATS-9R circumvents the immunogenicity and long-term integration risks typical of viral vectors. This enables controlled, short-term gene expression suitable for both discovery and preclinical therapeutic studies.

    4. Enhanced Reproducibility: As highlighted in the article "Solving Adipocyte Gene Silencing Challenges with ATS-9R", adopting ATS-9R in workflows improves data quality and reproducibility by minimizing off-target effects and enhancing delivery consistency—crucial for metabolic disease research models.

    5. Platform Flexibility: The nona-arginine peptide backbone facilitates efficient delivery of various nucleic acid cargos, including shRNA, siRNA, and CRISPR/Cas9 complexes, extending the platform's utility across gene knockdown and genome editing applications. For a comprehensive mechanistic discussion, see "ATS-9R: Precision Non-Viral Gene Delivery to White Adipose Tissue".

    Comparative Insights: Literature and Resource Integration

    Troubleshooting and Optimization Tips

    1. Inconsistent Transfection Efficiency

    • Complex Ratio Optimization: Confirm the 3:1 or 6:1 peptide:nucleic acid ratio. Suboptimal ratios may lead to incomplete condensation or aggregation, reducing delivery efficacy.
    • Nanoparticle Characterization: Use dynamic light scattering to ensure nanoparticle diameter remains within 150–354 nm. Larger aggregates may precipitate or exhibit poor cellular uptake.
    • Serum Interference: Always perform complexation in serum-free medium, as serum proteins can disrupt nanoparticle stability and decrease uptake.

    2. Gene Knockdown Variability

    • Target Validation: Use qPCR or Western blot to verify knockdown of target genes (e.g., >50% reduction in Fabp4 or CCL2 mRNA is typical with optimized protocols).
    • Cell Maturity: Ensure adipocytes are fully differentiated, as prohibitin is most abundant on mature cells. Oil Red O staining is recommended to confirm differentiation.

    3. Cytotoxicity or Off-Target Effects

    • Concentration Titration: Begin with lower peptide concentrations (10 μg/ml) and gradually increase to 25 μg/ml, monitoring cell viability (should remain >80%).
    • Fresh Preparation: Prepare complexes immediately before use to avoid peptide degradation or loss of targeting efficiency.

    4. In Vivo Delivery Issues

    • Injection Route: Intraperitoneal injection is preferred for optimal adipose tissue targeting. Monitor for signs of peritonitis or injection-related stress.
    • Clearance Timing: Plan tissue collection within 12–24 hours post-injection to capture peak tissue accumulation and gene knockdown.

    Future Outlook: Expanding Therapeutic and Research Horizons

    ATS-9R's modular design and proven efficiency in adipocyte targeting are paving the way for its adoption in diverse metabolic disease models—including insulin resistance, GDM, and obesity-induced type 2 diabetes. Its favorable safety profile, combined with the flexibility to deliver a range of nucleic acid therapeutics, positions it as a cornerstone in both basic and translational research.

    Emerging studies are exploring its integration with CRISPR/Cas9 genome editing and combinatorial therapies for adipose tissue remodeling, while advances in nanoparticle engineering may further enhance delivery specificity and efficiency. As new gene targets are identified in white adipose tissue, ATS-9R will remain a critical tool for dissecting metabolic pathways and validating therapeutic hypotheses.

    For a deeper dive into scenario-driven protocol enhancements and troubleshooting, consult "Solving Adipocyte Gene Delivery Challenges with ATS-9R", which complements the strategies outlined here with peer-reviewed, actionable guidance.

    Conclusion

    The ATS-9R (Adipocyte-targeting sequence-9-arginine) system from APExBIO offers a robust, reproducible, and safe solution for non-viral gene delivery to white adipose tissue. By embracing its stepwise protocols, leveraging advanced applications, and applying the troubleshooting insights detailed above, researchers can confidently accelerate discoveries in metabolic disease and obesity research.